Today, in San Diego on September 10, 2025, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company specializing in RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), revealed its plans to make an offering of its shares. This offering will be subject to market conditions and other relevant factors.